NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-CA-22-096 from the NIH Guide for Grants and Contracts
Notice NOT-CA-22-097 from the NIH Guide for Grants and Contracts
Notice NOT-CA-22-098 from the NIH Guide for Grants and Contracts
Notice NOT-MH-22-175 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AT-23-002 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit cooperative agreement applications to support multisite efficacy or effectiveness clinical trials of pharmacologic, nonpharmacologic, and/or multicomponent approaches for acute and/or chronic sickle cell disease (SCD) pain management, allowing continued opioid pain management as needed. However, opioid medication use alone should not be the only intervention studied. Trials supported under this initiative may also address the impact of these approaches on related psychological and functional outcomes to support improved overall well-being and quality of life. In addition, studies that address stigma, structural health care system, and social factors that may hinder quality comprehensive pain care for patients with SCD are also of interest. Investigators are encouraged to include the collection of well-justified biological markers or psychological processes that have demonstrated that they may mediate pain outcomes. Trials should collect sufficient measures to phenotypeclinically characterize participants such as type of pain, variability of pain, co-occurring conditions, and social determinants of health. The studies must address questions within the mission and research interests of the NIH HEAL Initiative and evaluate preventive or treatment strategies or interventions including medications, biologics, procedures, medical and assistive devices and technologies, behavioral interventions, rehabilitation strategies, complementary interventions, integrated approaches, and delivery system strategies in well controlled trials in patients with SCD to manage acute and/or chronic pain.
Funding Opportunity RFA-AT-23-001 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit cooperative agreement applications to conduct multisite embedded pragmatic or implementation trials to inform the uptake of pharmacologic, nonpharmacologic, and/or multicomponent approaches for acute and/or chronic sickle cell disease (SCD) pain management in health care systems that serve the SCD population. Trials may include or allow continuation of opioid medication as needed; however opioid medication use alone should not be the only intervention studied. Trials may propose methods to implement, improve adherence, or evaluate the effectiveness of guidelines for pain management in patients with SCD in various health care settings. Trials supported under this initiative could also address social and structural barriers such as stigma and racial bias to SCD pain management care.
Notice NOT-HD-22-029 from the NIH Guide for Grants and Contracts
Notice NOT-CA-22-110 from the NIH Guide for Grants and Contracts
Notice NOT-CA-22-111 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DA-23-051 from the NIH Guide for Grants and Contracts. In April 2018, the National Institutes of Health (NIH) launched the Helping to End Addiction Long-term Initiative or HEAL Initiative, an aggressive, trans-agency effort to speed scientific solutions to stem the national opioid public health crisis. Through this initiative, the National Institute on Drug Abuse, in partnership with other NIH Institutes, Centers, and Offices, requests applications for studies designed to develop and test interventions to prevent opioid misuse, opioid use disorder, and co-occurring conditionsby intervening on social determinants of health (SDOH). This initiative aims to build an evidence base for interventions that target malleable factors and conditions affecting the social context. Applications must seek to reduce health inequities in a U.S. population or population subgroup affected by the opioid crisis by studyingthe effects of a theory driven intervention on the prevention of opioid misuse/opioid use disorder and co-occurring conditions. Such conditions could include mental health conditions and/or suicide, and may alsoinclude other substance use and substance use-related outcomes. The research project must examinethe mechanisms by which the interventions exert their effects. Investigators should study interventions that are sustainable and easily taken to scale if effective.
Notice NOT-NS-22-095 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DK-22-016 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement invites applications to conduct a study to establish a longitudinal cohort of individuals who developed diabetes following SARS-CoV-2 infection to understand the pathophysiology and clinical course post-COVID diabetes. The cohort must include children and adults and reflect the geography and demographics of COVID-19 in the U.S. There must be an appropriate comparator population recruited and followed. The goals are to determine the contribution of: 1) specific pathophysiologic pathways; 2) overall health impact of the pandemic; 3) COVID-19 severity, and 4) COVID-19 treatment upon excess new onset diabetes from SARS-CoV-2 infection and response to diabetes therapy.The NIDDK strongly encourages Research on Sex/Gender Differences, Sexual and Gender Minority-Related Research and Race/Ethnic Diversity (see NOT-DK-22-003). This FOA aligns with the Mission and Vision of the NIDDK Strategic Plan for Research, including the theme of empowering a multidisciplinary workforce, engaging diverse stakeholders, and pursuing pathways to health for all. Specifically, this FOA aligns with the Scientific Goals (1.1 and 1.2) and Cross-cutting Topics (reducing health disparities and increasing health equity among racial and ethnic minority populations and others who are underserved) of the Strategic Plan.
Funding Opportunity PAR-22-203 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement is to solicit Technology Research and Development Center (TRDC) applications for the Point-of-Care Technologies Research Network (POCTRN). The POCTRN catalyzes innovation in medical technologies through a network model that enhances complementary strengths and builds multidisciplinary partnerships across scientific/technological, clinical, regulatory, and commercialization domains. Each TRDC will accelerate the development, validation, and deployment of point-of-care, home-based, and other innovative testing technologies in a specific area of health research. The POCTRN TRDCs will merge scientific and technological capabilities and expertise with clinical need and market demand to address unmet testing, monitoring, and treatment demands. This opportunity is open to all applicants, including the existing POCTRN grantees as well as new applicants.
Notice NOT-NS-23-008 from the NIH Guide for Grants and Contracts
Notice NOT-CA-22-113 from the NIH Guide for Grants and Contracts
Notice NOT-OD-22-168 from the NIH Guide for Grants and Contracts
Notice NOT-NR-22-015 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-22-192 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports applications to develop and implement a Clinical Coordinating Center (CCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website.This FOA will utilize a bi-phasic, milestone-driven cooperative agreement mechanism of award and runs in parallel with a companion FOA that encourages applications for a collaborating Data Coordinating Center (PAR-22-NNN). The objective of the CCC application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. Both a CCC application and a collaborating Data Coordinating Center (DCC) application must be submitted on the same application due date for consideration by NHLBI. Applicants are strongly encouraged to contact the appropriate Scientific/Research contact prior to submitting an application.
Funding Opportunity PAR-22-193 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports applications for a collaborating Data Coordinating Center (DCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website.This FOA will utilize a cooperative agreement mechanism of award and runs in parallel with a companion FOA (PAR-22-NNN) that encourages applications for a collaborating Clinical Coordinating Center (CCC). The objective of the DCC application is to present a comprehensive plan to provide overall project coordination, administration, data management, and biostatistical support for the clinical trial proposed in the collaborating CCC application.Both a DCC application and a collaborating CCC application must be submitted on the same application due date for consideration by NHLBI.
Notice NOT-AT-23-002 from the NIH Guide for Grants and Contracts